Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3231 Target Snapshot

Rho-associated protein kinase 1 · SINGLE PROTEIN · Homo sapiens

5,370Compounds
620Assays
18Approved Drugs
5,041.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13464. Use UniProt Q13464 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13464 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Rho-associated protein kinase 1 as ChEMBL target CHEMBL3231, mapped to UniProt Q13464. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Rho-associated protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3231
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13464
Rho-associated protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Rho-associated protein kinase 1 is the right protein anchor across sources, using UniProt Q13464 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRho-associated protein kinase 1
UniProt AccessionQ13464
Component TypeProtein
Sequence Length1354 aa

Rho-associated protein kinase 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Rho-associated protein kinase 1, mapped to UniProt Q13464. Sequence length is 1354 aa.

Mapped IDQ13464
Review nameRho-associated protein kinase 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

18
Approved
10
Phase III
19
Phase II
15
Phase I
Assay Mix

Activity Type Distribution

IC503,207.0
KI1,463.0
EC5025.0
KD346.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4753043 9.7 Ki 0.2 Preclinical
CHEMBL5901861 9.7 IC50 0.2 Preclinical
CHEMBL4107027 9.7 IC50 0.2 Preclinical
CHEMBL3902471 9.59 IC50 0.26 Preclinical
CHEMBL388978 9.55 Kd 0.28 Preclinical
CHEMBL3961538 9.41 IC50 0.39 Preclinical
CHEMBL5987641 9.4 IC50 0.4 Preclinical
CHEMBL5739910 9.4 IC50 0.4 Preclinical
CHEMBL3949136 9.37 IC50 0.43 Preclinical
CHEMBL388978 9.35 IC50 0.444 Preclinical
Distribution

pChEMBL Value Distribution

350
5.0
406
5.5
615
6.0
491
6.5
439
7.0
348
7.5
227
8.0
110
8.5
35
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPIVASERTIB
CHEMBL2325741
Approved 2023
BELUMOSUDIL
CHEMBL2005186
Approved 2021
UPADACITINIB
CHEMBL3622821
Approved 2019
NETARSUDIL
CHEMBL4594250
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

620
Total Assays
2,336
Tested Compounds
3
Assay Types
Binding — 617 assays, 2,336 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 492 1,945 6.6
assay format 57 249 6.5
cell-based format 54 124 6.7
subcellular format 14 18 6.2
Functional — 2 assays, 491 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 491 6.3
ADME — 1 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 9 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine